PYXS
Pyxis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.76
+4.76%Sep 29, 2026, 20:24 UTC
Pyxis Oncology, Inc. commenced a registered public offering of common stock, pre-funded warrants, and accompanying common warrants.
Sep 8, 2026, 11:42 UTC
Pyxis Oncology appointed John Flavin as Lead Independent Director, effective September 4, 2026.
Sep 8, 2026, 11:42 UTC
Pyxis Oncology appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026.
Aug 13, 2026, 11:00 UTC
Pyxis Oncology reported financial results for the quarter ended June 30, 2026.
Source:Aug 13, 2026, 11:00 UTC
Pyxis Oncology completed a private placement financing for up to $114 million, raising approximately $50 million in upfront gross proceeds to support patient follow-up and extend its cash runway into the second quarter of 2027.
Source:Jul 2, 2026, 00:00 UTC
Pyxis Oncology entered into a securities purchase agreement for a private placement of 19,600,153 common shares at $2.551 per share and warrants, expecting $50 million in gross upfront proceeds.